The Wall Street Journal dives into pharma research transparency: “Over the past few years, the pharmaceutical industry has been embroiled in controversy over access to clinical trial data. At issue is the ability for researchers to independently verify study results and, consequently, improve patient treatments that can lead to better health and lower costs. This sentiment has accelerated in light of various safety scandals that revealed data for some drugs was never fully published or disclosed.”
© 2023 Mad in America Foundation